TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

CORCEPT THERAP

OncologyMetabolicInfectious Disease
Pharma

CORCEPT THERAP is a pharmaceutical company focused on Oncology, Metabolic, Infectious Disease. Key products include KORLYM.

2012
Since
1
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

KORLYM
mifepristone
Metabolic
Glucocorticoid Receptor 5 indications · 2012

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 49%
0 drugs Phase 3: 2 Phase 2: 3 Phase 1: 5
Metabolic 26%
1 drugs Phase 2: 1 Phase 1: 2
Infectious Disease 21%
0 drugs Phase 2: 2 Phase 1: 4
Gastroenterology 5%
0 drugs Phase 1: 2

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Infectious Disease